CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 800 enrolled
Drug / intervention
Atosiban +1 moredrug
Likely dose
Atosiban 6.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01501214
NCT01501214Phase 4Completed

A Randomized Double Blind Comparison of Atosiban in Patients Undergoing in Vitro Fertilization Treatment

The University of Hong Kong·interventional·Posted Dec 29, 2011·Updated Jan 7, 2014

In Brief

A Phase 4 clinical trial evaluating Atosiban and Normal saline for Subfertility. Completed, enrolled 800 participants across 2 sites in 2 countries.

Detailed Summary

The hypothesis of this randomized double blind study is that the live birth rates are significantly higher after the use of atosiban prior to the embryo transfer in patients undergoing in vitro fertilization (IVF) treatment. This study aims to compare the live birth rates of IVF treatment between patients receiving atosiban and placebo prior to the transfer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubfertility
CountriesChina, Vietnam

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 29, 2011
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.5 years ago

Interventions

Atosibandrug

Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.

Normal salinedrug

Normal saline given